Study to Identify Blood and Skin Markers Predicting Response to Systemic Treatments in Chronic Inflammatory Skin Diseases

What this Trial Is About

Researchers are studying chronic inflammatory skin diseases, which include conditions affecting the skin and other organs such as joints and muscles. These diseases vary widely in how they progress and respond to treatments. The goal is to discover new cellular or molecular markers that can predict how well patients respond to systemic treatments after one year. This research also aims to improve understanding of these diseases, identify markers linked to clinical status over ten years, and find predictors of drug side effects. Participants include patients with moderate to severe chronic inflammatory skin diseases like atopic dermatitis, psoriasis, and others, as well as healthy controls who have undergone plastic surgery. The study involves collecting various biological samples such as blood, skin biopsies, skin swabs, hair follicles, and stool. These samples will be collected at different times, including at the start, four months, and one year, to analyze molecular, cellular, and microbiological markers. During the study, participants will undergo evaluations involving these biological sample collections to monitor immune signaling pathways, blood T cell populations, and skin gene activity. Researchers will also assess treatment responses, quality of life, and drug side effects at multiple points from inclusion up to ten years. This long-term follow-up allows detailed tracking of disease progression, treatment effectiveness, and safety over time.

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases